Tseng et al developed a nomogram for predicting survival of a woman with cervical cancer treated with concurrent chemoradiation. This can help to identify a patient who may benefit from more aggressive or novel therapies. The authors are from Taipei Veterans General Hospital and National Yang-Ming University in Taiwan.
Patient selection: Stage IIB to IVA
Parameters:
(1) age in years
(2) baseline serum SCC antigen concentration in ng/mL
(3) maximum tumor diameter in cm (on CT or MRI)
(4) parameterial invasion
(5) hydronephrosis
(6) invasion of bladder and/or rectum
(7) lymph node metastases
|
Age in Years |
Points |
|
<= 30 years |
0 |
|
30 to 90 years |
(0.9283 * (age in years)) - 27.849 |
|
> 90 years |
55.7 |
|
Parameter |
Finding |
Points |
|
SCC antigen |
< 1.6 in ng/mL |
0 |
|
|
1.6 to 5.0 |
11.1 |
|
|
5.1 to 15 |
22.6 |
|
|
> 15 |
34 |
|
tumor size |
< 4 cm |
0 |
|
|
4 to 6 cm |
13.7 |
|
|
> 6 |
30.9 |
|
parametrial invasion |
absent |
0 |
|
|
present |
16.9 |
|
hydronephrosis |
absent |
0 |
|
|
present |
20.6 |
|
bladder and/or rectum invasion |
absent |
0 |
|
|
present |
28.2 |
|
lymph node metastases |
absent |
0 |
|
|
pelvic |
16.8 |
|
|
para-aortic |
34.3 |
total score =
= SUM(points for all 7 parameters)
Interpretation:
• minimum score: 0
• maximum score: 221
• The higher the score the worse the prognosis
|
Score |
Mean Survival in Months |
|
<27.3 |
> 56 months |
|
|
62.92 - (0.2589 * (points)) |
|
> 216 |
< 6 months |
Limitation:
• The method for quantitating the SCC antigen and the normal reference range were not mentioned.
Specialty: Hematology Oncology, Surgery, general, Obstetrics & Gynecology
ICD-10: ,
